New Drug Reimbursement Recommendation for Pomalyst
The Canadian Agency for Drugs and Technologies in Health recommanded the reimbursement for Pomalidomide (...
Read moreResearch & Access Updates
The 10th Edition of the Myeloma Canada Scientific Roundtable was a Great Success
On October 4th and 5th, leading hematologists and myeloma researchers from around the country and the Uni...
Read moreDaratumumab (Darzalex) is Now Available in Newfoundland
As of Aug 16, 2019, Darzalex has been approved in Newfoundland, in combination with Lenalidomide and Dexa...
Read moreDarzalex Now Listed in Saskatchewan!
As of July 15, Darzalex (daratumumab) has been approved in Saskatchewan, in combination with lenalidomide...
Read moreHealth Canada Approves Pomalyst-Based Triplet Combination
On July 10, 2019, Celgene Inc. announced that Health Canada...
Read moreThe 2019 European Hematology Association (EHA) Annual Meeting
We’ve just returned from the 2019 European Hematology Association (EHA) Annual Meeting where Prof Maria-V...
Read more